127 related articles for article (PubMed ID: 37313917)
21. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
Mezvrishvili Z; Managadze L
Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
[TBL] [Abstract][Full Text] [Related]
22. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
23. The role of radiation therapy in the treatment of testicular germ cell tumors.
Marks LB; Anscher MS; Shipley WU
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1143-72. PubMed ID: 1663938
[TBL] [Abstract][Full Text] [Related]
24. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment.
Pentheroudakis G; De Bono JS; Kaye SB; Simpson A; Paul J; Brown I; Pamenter B; Kirk A; Vasey P; Raby N; Kirk D
BJU Int; 2003 Jul; 92(1):36-42. PubMed ID: 12823380
[TBL] [Abstract][Full Text] [Related]
25. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report.
Terakawa T; Miyake H; Muramaki M; Takenaka A; Fujisawa M
Int J Urol; 2010 Oct; 17(10):881-5. PubMed ID: 20731738
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
27. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.
Wood DP; Herr HW; Heller G; Vlamis V; Sogani PC; Motzer RJ; Fair WR; Bosl GJ
J Urol; 1992 Dec; 148(6):1812-5; discussion 1815-6. PubMed ID: 1331547
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
29. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
30. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
31. Ejaculatory function in stage T1 nonseminomatous germ cell tumors: retroperitoneal lymph node dissection versus surveillance--a decision analysis.
Langenstroer P; Rosen MA; Griebling TL; Thrasher JB
J Urol; 2002 Oct; 168(4 Pt 1):1396-401. PubMed ID: 12352401
[TBL] [Abstract][Full Text] [Related]
32. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
Nason GJ; Jewett MAS; Bostrom PJ; Goldberg H; Hansen AR; Bedard PL; Sturgeon J; Warde P; Chung P; Anson-Cartwright L; Sweet J; Atenafu EG; O'Malley M; Hamilton RJ
Eur Urol Oncol; 2021 Apr; 4(2):289-296. PubMed ID: 32907779
[TBL] [Abstract][Full Text] [Related]
33. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
34. Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.
Ghodoussipour S; Daneshmand S
Urol Clin North Am; 2019 Aug; 46(3):389-398. PubMed ID: 31277733
[TBL] [Abstract][Full Text] [Related]
35. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
36. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
40. Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
Luz MA; Kotb AF; Aldousari S; Brimo F; Tanguay S; Kassouf W; Aprikian AG
World J Surg Oncol; 2010 Nov; 8():97. PubMed ID: 21062470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
